Immunomonitoring Core
免疫监测核心
基本信息
- 批准号:8063561
- 负责人:
- 金额:$ 23.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AntibodiesAntigensArtsBindingBiological AssayBiological MarkersBloodCD8B1 geneCell Culture TechniquesClinicalCollaborationsCore FacilityDataDatabasesDevelopmentEpitopesFigs - dietaryGene Expression ProfileGenomicsGoalsImmunityIndividualInstitutesLiquid substanceMeasuresNasal Lavage FluidPeptidesResearchSamplingSerumT cell responseT-LymphocyteT-Lymphocyte EpitopesTechnologyTestingVaccinatedVaccinescell typefluimmunoreactivityimprovedmucosal vaccinenonhuman primatetool
项目摘要
Comprehensive immunological assessments are critical to improve vaccines. Recent studies have
emphasized the importance of incorporating repertoire analysis in the assessment of vaccine-induced T cell
efficacy. Immunomonitoring Core will provide the information (such as T cell epitopes, type of T cell
responses, Ab titer) and tools (such as tetramers) required to perform the research in all the Projects
through the expertise and state-of-the art technologies. The primary objectives of the Immunomonitoring
Core are: AIM 1: To provide state-of-the-art analysis of the Flu antigen-specific T cell repertoires (EpiMax).
T cell repertories specific for Flu antigens (H1 HA, M2, and NP) will be comprehensively analyzed at a
peptide level with samples obtained from healthy individuals (from Sample Core), Flu-vaccinated subjects,
and Flu-infected subjects (from Clinical Core). The epitopes (for CD4+ and CD8+ T cells), the type, and the
magnitude of Flu-specific T cell responses will be determined. AIM 2: To provide state-of-art analysis of
multiple Flu-antigen-specific antibody liters (Ab Luminex). Flu-antigen (H1HA, H5 HA, M1; M2, and
NP)-specific antibodies will be measured by the assay developed at the Institute in a platform of Luminex.
AIM 3: To provide Flu-antigen derived peptide/HLA class I or class II tetramers. The T cell epitopes
identified in EpiMax assay will be tested for the binding to HLA class I or II molecules, and the tetramers will
be generated at Dr. Sekaly's lab. AIM 4: To perform cell cultures with the identified Flu antigen epitopes for
genomic Immunoreactivity profiles. Global gene expression profile of PBMCs and nasal wash samples
cultured with the T cell epitope peptide identified with EpiMax will be analyzed in the collaboration with
Microarray Core. Thus, Immunomonitoring Core will extensively interact with other Core facilities and all the
Projects towards the common goals: development of mucosal vaccines, and establishment of biomarkers of
protective immunity.
全面的免疫学评估对于改进疫苗至关重要。最近的研究
强调了在评估疫苗诱导的T细胞免疫应答中结合库分析的重要性。
功效免疫监测核心将提供信息(如T细胞表位、T细胞类型),
反应,抗体滴度)和工具(如四聚体)进行研究所需的所有项目
通过专业知识和最先进的技术。免疫监测的主要目标
核心是:目的1:提供流感抗原特异性T细胞库(EpiMax)的最新分析。
流感抗原(H1 HA、M2和NP)特异性T细胞库将在
肽水平与从健康个体(来自样品核心),流感疫苗接种受试者,
和流感感染受试者(来自临床核心)。表位(CD 4+和CD 8 + T细胞)、类型和免疫原性。
将确定流感特异性T细胞应答的大小。目的2:提供以下方面的最新分析:
多个流感抗原特异性抗体升数(Ab Luminex)。流感抗原(H1 HA、H5 HA、M1、M2和
NP)特异性抗体将通过该研究所在Luminex平台上开发的测定法来测量。
目的3:提供流感抗原衍生肽/HLA I类或II类四聚体。的T细胞表位
将测试在EpiMax测定中鉴定的四聚体与HLA I类或II类分子的结合,并且四聚体将
在塞卡利博士的实验室里产生目的4:用鉴定的流感抗原表位进行细胞培养,
基因组免疫反应性谱。PBMC和鼻洗液样品的总体基因表达谱
与EpiMax鉴定的T细胞表位肽一起培养的细胞将与
微阵列核心。因此,免疫监测核心将广泛地与其他核心设施和所有
共同目标项目:粘膜疫苗的开发和生物标志物的建立
保护性免疫
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hideki Ueno其他文献
Hideki Ueno的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hideki Ueno', 18)}}的其他基金
Elucidating the Mode of Action of "Tfh-like" Resident Memory CD4+T cells in Human Lung
阐明人肺中“Tfh 样”常驻记忆 CD4 T 细胞的作用模式
- 批准号:
10039182 - 财政年份:2020
- 资助金额:
$ 23.33万 - 项目类别:
Elucidating the mode of action of "Tfh-like" resident memory CD4+ T cells in human lung
阐明人肺中“Tfh 样”常驻记忆 CD4 T 细胞的作用模式
- 批准号:
10453372 - 财政年份:2020
- 资助金额:
$ 23.33万 - 项目类别:
Altered T follicular helper responses in human autoimmune diseases
人类自身免疫性疾病中滤泡辅助 T 反应的改变
- 批准号:
8732917 - 财政年份:2014
- 资助金额:
$ 23.33万 - 项目类别:
Dysregulation of CXCR5+ B Helper T Cell Subsets in Dermatamyositis
皮肌炎中 CXCR5 B 辅助 T 细胞亚群的失调
- 批准号:
8377375 - 财政年份:2012
- 资助金额:
$ 23.33万 - 项目类别:
Vaccine Induced Activation of T Follicular Helper Cell Subsets
疫苗诱导滤泡辅助 T 细胞亚群的激活
- 批准号:
8307073 - 财政年份:2011
- 资助金额:
$ 23.33万 - 项目类别:
Dysregulation of CXCR5+ B Helper T Cell Subsets in Dermatamyositis
皮肌炎中 CXCR5 B 辅助 T 细胞亚群的失调
- 批准号:
7687208 - 财政年份:2009
- 资助金额:
$ 23.33万 - 项目类别:
Dysregulation of CXCR5+ B Helper T Cell Subsets in Dermatamyositis
皮肌炎中 CXCR5 B 辅助 T 细胞亚群的失调
- 批准号:
8065464 - 财政年份:
- 资助金额:
$ 23.33万 - 项目类别:
Dysregulation of CXCR5+ B Helper T Cell Subsets in Dermatamyositis
皮肌炎中 CXCR5 B 辅助 T 细胞亚群的失调
- 批准号:
8470123 - 财政年份:
- 资助金额:
$ 23.33万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 23.33万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别: